Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
- May 18th, 2023
- 264 views
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance.
Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price target of $60 by Truist. In pre-market trading, $ACLX is currently trading at $41.34, with a slight increase of $0.10 (+0.24%).
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has received a Buy rating from Canaccord Genuity, along with a price target of $48. $PLRX is trading at $21.75 in pre-market, showing a gain of $0.22 (+1.02%).
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has been initiated with a Buy rating by Guggenheim. In pre-market trading, $TARS is trading at $16.41, experiencing a significant increase of $0.48 (+3.01%).
Varonis Systems, Inc. (Nasdaq: VRNS) has received a Buy rating and a price target of $30 from DA Davidson. However, in pre-market trading, $VRNS is currently trading at $22.81, facing a decrease of $1.20 (-5.00%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login